CLEC16A in astrocytes promotes mitophagy and limits pathology in a multiple sclerosis mouse model

CLEC16A在星形胶质细胞中促进线粒体自噬,并限制多发性硬化症小鼠模型中的病理变化。

阅读:3
作者:Atsushi Kadowaki ,Michael A Wheeler,Zhaorong Li,Brian M Andersen,Hong-Gyun Lee,Tomer Illouz,Joon-Hyuk Lee,Alain Ndayisaba,Stephanie E J Zandee,Himanish Basu,Chun-Cheih Chao,Joao V Mahler,Wendy Klement,Dylan Neel,Matthew Bergstresser,Veit Rothhammer,Gabriel Lipof,Lena Srun,Scott A Soleimanpour ,Isaac Chiu,Alexandre Prat,Vikram Khurana ,Francisco J Quintana

Abstract

Astrocytes promote neuroinflammation and neurodegeneration in multiple sclerosis (MS) through cell-intrinsic activities and their ability to recruit and activate other cell types. In a genome-wide CRISPR-based forward genetic screen investigating regulators of astrocyte proinflammatory responses, we identified the C-type lectin domain-containing 16A gene (CLEC16A), linked to MS susceptibility, as a suppressor of nuclear factor-κB (NF-κB) signaling. Gene and small-molecule perturbation studies in mouse primary and human embryonic stem cell-derived astrocytes in combination with multiomic analyses established that CLEC16A promotes mitophagy, limiting mitochondrial dysfunction and the accumulation of mitochondrial products that activate NF-κB, the NLRP3 inflammasome and gasdermin D. Astrocyte-specific Clec16a inactivation increased NF-κB, NLRP3 and gasdermin D activation in vivo, worsening experimental autoimmune encephalomyelitis, a mouse model of MS. Moreover, we detected disrupted mitophagic capacity and gasdermin D activation in astrocytes in samples from individuals with MS. These findings identify CLEC16A as a suppressor of astrocyte pathological responses and a candidate therapeutic target in MS.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。